Oppenheimer analyst Mark Breidenbach reiterated a Buy rating on Iovance Biotherapeutics Inc (IOVA) today. The company’s shares opened today at $10.42.
According to TipRanks.com, Breidenbach is a 3-star analyst with an average return of 1.3% and a 43.6% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences Inc, Global Blood Therapeutics, and Sorrento Therapeutics.
Currently, the analyst consensus on Iovance Biotherapeutics Inc is a Strong Buy with an average price target of $24.80.
See today’s analyst top recommended stocks >>
Based on Iovance Biotherapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $32.58 million. In comparison, last year the company had a GAAP net loss of $25.85 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors.
